Compare SOPA & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOPA | XRTX |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | Singapore | Canada |
| Employees | N/A | N/A |
| Industry | EDP Services | Pharmaceuticals and Biotechnology |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2M | 4.3M |
| IPO Year | 2021 | 2018 |
| Metric | SOPA | XRTX |
|---|---|---|
| Price | $0.17 | $2.54 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $22.50 | N/A |
| AVG Volume (30 Days) | 567.8K | ★ 1.7M |
| Earning Date | 05-19-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,171,635.00 | N/A |
| Revenue This Year | $2.43 | N/A |
| Revenue Next Year | $71.20 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 45.00 | N/A |
| 52 Week Low | $0.25 | $0.35 |
| 52 Week High | $6.28 | $3.60 |
| Indicator | SOPA | XRTX |
|---|---|---|
| Relative Strength Index (RSI) | 22.52 | 54.38 |
| Support Level | N/A | $0.47 |
| Resistance Level | $0.66 | $3.03 |
| Average True Range (ATR) | 0.04 | 0.26 |
| MACD | -0.01 | -0.13 |
| Stochastic Oscillator | 9.68 | 53.15 |
Society Pass Inc is building an ecosystem of platforms and technology-enabled companies that synergistically work together to transform how consumers and merchants interact with one another in Southeast Asia and South Asia. Through the acquisition of companies and partnerships with entrepreneurs, the company meets the growing demand for services in sectors such as lifestyle, beauty, travel, and food and beverage. The company currently operates in Six reportable operating segments: Online Grocery and Food deliveries, Digital marketing, Online ticketing and reservation, Telecommunications Reseller, e-commerce, and Corporate. The company generates the majority of its revenue from the Digital marketing segment.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.